Logo image of AGEN

AGENUS INC (AGEN) Stock Fundamental Analysis

USA - NASDAQ:AGEN - US00847G8042 - Common Stock

3.97 USD
-0.08 (-1.98%)
Last: 10/14/2025, 8:00:00 PM
4.02 USD
+0.05 (+1.26%)
After Hours: 10/14/2025, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AGEN. AGEN was compared to 536 industry peers in the Biotechnology industry. AGEN has a bad profitability rating. Also its financial health evaluation is rather negative. AGEN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.
AGEN had a negative operating cash flow in the past year.
AGEN had negative earnings in each of the past 5 years.
In the past 5 years AGEN reported 4 times negative operating cash flow.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

AGEN has a Return On Assets of -89.45%. This is in the lower half of the industry: AGEN underperforms 72.95% of its industry peers.
Industry RankSector Rank
ROA -89.45%
ROE N/A
ROIC N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

With an excellent Gross Margin value of 99.37%, AGEN belongs to the best of the industry, outperforming 98.13% of the companies in the same industry.
In the last couple of years the Gross Margin of AGEN has remained more or less at the same level.
AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AGEN has more shares outstanding
The debt/assets ratio for AGEN is higher compared to a year ago.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -19.27, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
AGEN has a Altman-Z score of -19.27. This is amonst the worse of the industry: AGEN underperforms 84.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.27
ROIC/WACCN/A
WACC9.44%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

2.3 Liquidity

A Current Ratio of 0.06 indicates that AGEN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.06, AGEN is doing worse than 97.95% of the companies in the same industry.
A Quick Ratio of 0.06 indicates that AGEN may have some problems paying its short term obligations.
AGEN's Quick ratio of 0.06 is on the low side compared to the rest of the industry. AGEN is outperformed by 97.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.06% over the past year.
The Revenue for AGEN has decreased by -36.29% in the past year. This is quite bad
Measured over the past years, AGEN shows a decrease in Revenue. The Revenue has been decreasing by -7.17% on average per year.
EPS 1Y (TTM)37.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.32%
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%9.28%

3.2 Future

Based on estimates for the next years, AGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.43% on average per year.
Based on estimates for the next years, AGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.58% on average per year.
EPS Next Y111.27%
EPS Next 2Y36.57%
EPS Next 3Y20.76%
EPS Next 5Y14.43%
Revenue Next Year52.97%
Revenue Next 2Y10.81%
Revenue Next 3Y1.88%
Revenue Next 5Y15.58%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

AGEN's earnings are expected to grow with 20.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.57%
EPS Next 3Y20.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGENUS INC

NASDAQ:AGEN (10/14/2025, 8:00:00 PM)

After market: 4.02 +0.05 (+1.26%)

3.97

-0.08 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners29.93%
Inst Owner Change0%
Ins Owners1.71%
Ins Owner Change0.33%
Market Cap126.48M
Analysts80
Price Target12.58 (216.88%)
Short Float %8.04%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-66.73%
Min EPS beat(2)-172.44%
Max EPS beat(2)38.98%
EPS beat(4)2
Avg EPS beat(4)-35.41%
Min EPS beat(4)-172.44%
Max EPS beat(4)38.98%
EPS beat(8)4
Avg EPS beat(8)-41.25%
EPS beat(12)6
Avg EPS beat(12)-28.23%
EPS beat(16)9
Avg EPS beat(16)-17.97%
Revenue beat(2)0
Avg Revenue beat(2)-29.94%
Min Revenue beat(2)-49.33%
Max Revenue beat(2)-10.55%
Revenue beat(4)0
Avg Revenue beat(4)-24.86%
Min Revenue beat(4)-49.33%
Max Revenue beat(4)-10.55%
Revenue beat(8)1
Avg Revenue beat(8)-15.24%
Revenue beat(12)4
Avg Revenue beat(12)-4.78%
Revenue beat(16)7
Avg Revenue beat(16)3.5%
PT rev (1m)0%
PT rev (3m)7.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)989.89%
EPS NY rev (1m)428.37%
EPS NY rev (3m)142.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)123.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)28.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.15
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-4.01
FCFYN/A
OCF(TTM)-4.01
OCFYN/A
SpS3.19
BVpS-11.13
TBVpS-11.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.37%
FCFM N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
F-Score2
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.66%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -19.27
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)280.5%
Cap/Depr(5y)277.58%
Cap/Sales(3y)20.35%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.32%
EPS Next Y111.27%
EPS Next 2Y36.57%
EPS Next 3Y20.76%
EPS Next 5Y14.43%
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%9.28%
Revenue Next Year52.97%
Revenue Next 2Y10.81%
Revenue Next 3Y1.88%
Revenue Next 5Y15.58%
EBIT growth 1Y19.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.17%
EBIT Next 3Y-10.15%
EBIT Next 5Y-10.98%
FCF growth 1Y45.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.49%
OCF growth 3YN/A
OCF growth 5YN/A